Lv0
0 积分 2023-04-11 加入
ALK Inhibitor and Chemotherapy Combinations in Models of ALK-Translocated NSCLC
1天前
待确认
Anti-EGFR therapy can overcome acquired resistance to the third-generation ALK-tyrosine kinase inhibitor lorlatinib mediated by activation of EGFR
6天前
已完结
KRAS inhibition in metastatic colorectal cancer: An update
28天前
已完结
Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases
2个月前
已完结
Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases
3个月前
已完结
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
5个月前
已完结
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
7个月前
已完结
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
8个月前
已完结
Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease
11个月前
已完结
In vivo and in vitro inhibition of SCLC by combining dual cancer-specific recombinant adenovirus with Etoposide
11个月前
已完结
皖公网安备34019202002308
